No pharmaceutical opinion available for this interaction.
Possible decrease of clinical efficacy.
Association not recommended and more particularly with raltegravir HD 1200 mg QD.
Choose another antiretroviral therapy.
If this combination is used, increase the dose of raltegravir to 800 mg BID.
Monitor for signs and symptoms of therapeutic failure.
Cytosolic system, UGT
3A4, P-gp, UGT
2C19 (mostly if > 1200 mg/d)
If possible, consider an alternative.
Gabapentin, pregabalin, valproic acid, clobazam, leviracetam, topiramate, lacosamide, clonazepam or lamotrigine.
Viral load HIV
Raltegravir plasma level
Ref #2152 : Coadministration has not been studied. The product monograph does not suggest dose adjustment with raltegravir and anticonvulsants. However, it suggests with rifampin (potent UGT inducer) an increase in the dose of raltegravir to 800 mg BID.
See raltegravir + rifampin.